Akebia Corp (AKBA) - Long-Term Debt to Capital Coefficient

Akebia Therapeutics distributes its medications through an extensive network of wholesalers, ensuring a seamless supply to pharmacies. The asset's market dynamics on GURU.Markets, where the indicator stands at 6.55, reflect the evolution of a therapeutic environment that integrates the company's products into standard treatments for renal pathologies. Patent protection for key products and close collaboration with the largest dialysis centers in the US ensure the business's resilience.

Institutional capital assesses the stability of Akebia Therapeutics (AKBA) through the balance of credit load and equity, which determines the issuer's investment attractiveness. By analyzing the ratio of long-term debt to equity, an investor can see the share of liabilities with a maturity of more than one year, which, coupled with stable cash flows from anemia drug sales, confirms the asset's financial reliability and the absence of critical dependence on borrowed funds.